To the Editor, While pre-analytical errors are today increasingly characterized, several analytical concerns have emerged, particularly for interferences with immunoassays [1, 2] . Hereby, we report the case of a 31-year-old Belgian woman with thyroid and steroid hormones levels that were incompatible with her clinical condition.
The patient and her husband consulted our fertility clinic for male infertility. She had had an uneventful pregnancy 3 years before and a recent early miscarriage, both after intrauterine insemination. Several hormonal measurements were requested on our Cobas 8000 ® analyzer (Roche-Diagnostics, Basel, Switzerland): thyroid function tests revealed a normal thyroid stimulating hormone (TSH) (0.68 mIU/L -reference range (RR): [0.27-4.20]), a normal free-thyroxine (FT4) (14.7 pmol/L -RR: [10- were also observed on a blood sample obtained on day 3 of the cycle, thus during early follicular phase (which was confirmed by an ovarian ultrasound performed at the same time). On the other hand, other hormones like luteinizing hormone (LH), follicular stimulating hormone (FSH), aldosterone, 17-hydroxy(OH)-progesterone and androstenedione levels were strictly normal according to their cycle-related reference range. Even in the absence of menstrual dysfunction, a magnetic resonance imaging (MRI) of the pelvis and of the upper abdomen were performed in order to exclude a possible secretory tumor. Ovaries and adrenal glands of normal size and appearance were visualized. Given the discordance between clinical and radiological features and biochemical results, a multiple assay interference was suspected, and the laboratory team was alerted.
To confirm and characterize this interference, different procedures were undertaken. We first sent the serum of the patient to another laboratory which uses two different analyzers to perform these dosages: the Vitros 5600 with these other analyzers (Table 2) . Additionally, testosterone levels also fell within the normal range when measured with a well-validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method (6460 Triplequad LC/MS, Agilent Technologies, Waldbronn, Germany. Linearity-range: 0.1040-104.01 nmol/L). Therefore, it was obvious that an undetermined interference was present.
We next performed a dilution test with the manufacturer's universal diluent. Post-dilution values (%) were all comprised between the reference values determined, excepted for TSH, DHEA-S and testosterone, possibly reflecting a higher robustness of these assays against the interference (Table 2) . Heterophilic antibody blocking tubes (HBT -Scantibodies, Santee, CA, USA) were also used to explore the possible presence of heterophilic antibodies. This treatment led to a major decrease in testosterone level (Table 1) . For FT3, the decrease was less marked, but the concentration obtained fell into the physiological range (Table 1) . DHEA-S post-treatment levels were still more than twice as high as the upper limit of normality. On the other hand, TSH levels increased about 173% (0.65 to 1.12 mIU/mL). Post-HBT values for anti-TPO and anti-Tg antibodies were not reported as HBTs are designed for antigen assays only. The polyethylene glycol precipitation procedure (PEG6000, 25% w/w) was also applied by adding equal volumes of serum and PEG solution as previously described [3] . Percentage recoveries (%) were obtained with the formula: [concentration after PEG treatment × 2]/[concentration before PEG treatment]. Based on this test, recoveries observed for DHEA-S, testosterone and FT3 were clearly lower as compared to their reference ranges while the TSH recovery was above the reference range. These observations argue for the presence of an interference composed of antibodies (Table 1 ) [2] . Indeed, PEG is an agent well-known to induce antibodies or macrocomplexes precipitation by lowering their solubility. Of note, the protein electrophoresis analysis was strictly normal as a recent paper also reported falsely elevated steroid hormones due to an IgG k gammopathy [4] . Analytical interferences due to endogenous antibodies are estimated to be present in almost 4% of all tested samples [5] . Moreover, biotin interference cases, mainly encountered in cases of therapeutic supplementation, have been frequently reported [2, 5] . However, other rarer causes are sometimes reported like heterophilic antibodies, human anti-animal antibodies, rheumatoid factor, paraproteins or anti-streptavidin antibodies (ASA) [1, 2, 4] .
At this stage of our investigations, due to the confirmed lack of intake of any dietary supplement containing biotin and the bidirectional nature of the interference, our main hypothesis was the presence of anti-streptavidin anti bodies (ASA). In order to verify this presumption, we applied the protocol previously defined by Piketty et al. [6] . Initially defined to remove the interference due to biotin, it is also effective in this case as the streptavidin-coated beads will bind to ASA [2, 6, 7] . Following this treatment, we were able to confirm the presence of ASA (Table 1) . Several hormones reached normal values (FT3, DHEA-S and anti-Tg antibodies) while testosterone and anti-TPO antibodies remained slightly above normal values. This latter observation may be explained by the fact that this kind of interference needs probably to scale up the streptavidin beads/ serum ratio as compared to biotin [7] . Finally, an aliquot of the sample was sent to the Roche ® Diagnostics facilities (Penzberg, Germany) where they also confirmed the presence of ASA in the serum of our patient. Nowadays, the biotin-streptavidin immobilization system is widely used in immunoassays, thanks to its high affinity and specificity. This bridge system is used both for immunometric and competitive assays on the Cobas ® platform. In both cases ASA are able to bind streptavidincoated beads, leading to a reduced signal generation. However, in competitive immunoassays, the signal is inversely proportional to the targeted antigen concentration. This probably explain why our interference gave false positive results in competitive assays (i.e.: FT3, FT4, DHEA-S, testosterone, anti-TPO or anti-Tg antibodies) and a falsely reduced value in the only immunometric assay (TSH) ( Table 1 ). Interestingly this interference seems to affect greater competitive assays but, unfortunately, we were not able to identify the cause [8, 9] .
Many immunoassay platforms use the streptavidinbiotin immobilization system. However, some of these seem more prone to this type of interference than others. The reasons are not-well determined but are probably multifactorial. Indeed, this could be due to different sample dilution factor, the nature of the streptavidin used (recombinant or purified) or the coating-process of this latter. In our case, TSH and testosterone as measured on the Ortho Vitros 5600 ® assays do not use streptavidincoated beads but streptavidin is directly coated on the reaction cup well, therefore being present throughout the reaction process. On the other hand, FT4 and FT3 on the Vitros 5600 ® and Architect i1000SR ® assays do not use the streptavidin-biotin couple.
Several interference cases due to biotin and ASA have already been reported [2, [6] [7] [8] [9] [10] . ASA interferences have been less frequently described but are probably largely unrecognized as a recent study showed that 0.6% of specimens tested for anti-CCP had a false positive result due to the presence of ASA [7] . First described in 2013, these antibodies mainly affect the thyroid hormone profile, leading to a factitious hyperthyroidism pattern [7] [8] [9] . However, they also seem to occasionally affect other laboratory tests when an expanded investigation is performed [8, 10] . In the present report, although the patient was clinically euthyroid, the initial (factitious) diagnosis of autoimmune thyroiditis was consistent with the context of miscarriage and the main clinical alert came from unexplained excess of several steroids.
Unfortunately, we were not able to confirm if these ASA also affected E2 and progesterone measurements given the lack of residual samples, but this seems very likely. In the meantime, the patient became pregnant and this status rendered further evaluation of interferences e258 Bayart et al.: Erroneous hormones profile due to anti-streptavidin antibodies difficult. Another limitation of our study was the fact that our alternative methods were also streptavidin-biotin based assays for some parameters (TSH and testosterone). Therefore, although physiological values were observed for all tested parameters, we could not prove that these assays were not affected by the interfering antibodies. Our patient gave her informed consent for investigation but, for obvious reasons of reliability, was redirected to another laboratory for the biological monitoring of her pregnancy. Moreover, these results led to a lot of anxiety in our patient for several weeks, a consequence so far insufficiently emphasized.
The identification of interferences can be challenging. Moreover, a single test is rarely sufficient to clearly identify an interference. Only a judicious combination of several tests can exclude or identify this latter [2] . In case of anti-streptavidin suspicion, we recommend performing streptavidin beads treatment before HBT and PEG treatment as these latter two seem less powerful to remove such interfering antibodies, as reported by us and previously by another team [9] .
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